Markham, Canada (PressExposure) August 28, 2009 -- BTNX Inc. has launched a Rapid ResponseÂ® advanced FDA cleared & CLIA waived in-vitro diagnostic group A streptococcus, or strep A, test, which is a qualitative lateral flow immunoassay for the detection of strep A carbohydrate antigen in a throat swab.
Strep A is a bacterium that is commonly found in the throat and on the skin. Strep A bacteria might cause no symptoms of disease, but they can also cause infections that range from mild to life-threatening.
Strep A bacteria are spread by direct person-to-person contact. The bacteria are carried in discharges from nose or throat of an infected person and in infected wounds or sores on the skin. The bacteria are usually spread when infected secretions come in the contact with the mouth, nose, or eyes of an uninfected person.
Strep A bacteria usually causes relatively mild illnesses, such as streptococcal sore throat (strep throat) and streptococcal skin infections (impetigo). It can also cause more serious illnesses such as scarlet fever, rheumatic fever, postpartum fever, wound infections, and pneumonia.
Occasionally, a deadly type of strep A bacteria can invade the blood, muscle and fat tissue, or lungs and cause a serious and often life- threatening type infections.
Rapid ResponseÂ® Strep A test is FDA cleared and CLIA waived, offers 95% accuracy v/s culture (gold Stand) in rare and 1+ colonies and results within 5 minutes, and has no cross reaction with other ?-hemolytic streptococci.
Rapid ResponseÂ® branded tests are trusted by professionals in laboratories, physiciansâ offices, hospitals and clinics worldwide for their diagnostic testing requirements.
For more information about the products please visit [http://www.BTNX.com], or contact Sales@BTNX.com.